Dataset from A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 for 12 Weeks in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to evaluate specific alterations in immune cell mechanisms
related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger
ribonucleic acid (mRNA) extracted from induced sputum in patients experiencing an
exacerbation of COPD, with or without treatment with GSK2269557. The efficacy of treatment
with GSK2269557 will also be measured using functional respiratory imaging (FRI) and
spirometry. This is a randomised, double-blind, placebo-controlled, parallel-group study. The
study consisted of Screening Phase (up to 3 days prior to Day 1), Treatment Phase (Days 1 to
84) and Follow phase (7 to 14 days after last dose). The total duration of the study is 13-14
weeks including the screening visit. DISKUS TM and ELLIPTA TM are registered trademark of GSK
group of companies.